MedPal AI Acquires Remedi Pharmacy Assets, Eyes Breakeven at 80,000 Items Per Month

Put bluntly, MedPal is trying to bridge the gap from roughly 42,000 items per month today to 80,000 items per month for pharmacy-level breakeven. If it can reactivate enough of Remedi’s former patient base and care home contracts, the maths starts to look a lot more interesting.

Key figure	Amount
Total acquisition cost	£310,000
Runcorn prescription items in 2024	1 million
Historical annualised turnover at current NHS average item values	Approximately £10 million
Peak monthly items at Runcorn in 2024	Over 100,000
Peak monthly items at Swaffham in 2024	Over 30,000
March group dispensing volume	Over 40,000 items
Current dispensing volume quoted by CEO	42,000 items per month
Pharmacy-level EBITDA breakeven target	80,000 items per month
NHS pharmacy gross margin	In excess of 34%

How the Remedi deal was structured – and why the related party angle needs attention

This was not a simple one-step acquisition. Remedi had entered administration on 6 December 2024, and MedPal’s CEO, Jason Drummond, had previously entered into a conditional sale and purchase agreement in October 2025 to acquire the trade and assets.

He paid £30,000 to secure that right and also paid Castlebridge Finance Limited £250,000 to release security over Remedi’s assets. A further approximately £1,000 was spent setting up New Performance Health Limited, or NPH, which took a lease over new premises in Runcorn on 8 April 2026.

On 28 April 2026, MedPal Limited stepped into that agreement via a deed of novation. A novation is just a legal transfer of rights and obligations from one party to another. On completion, MedPal Limited reimbursed Mr Drummond’s total costs of £280,000 and paid the final £30,000 under the original agreement, taking total consideration to £310,000.

Because the CEO was involved personally before the company stepped in, this counts as a related party transaction under the AIM Rules. The independent directors, excluding Mr Drummond, said the terms are fair and reasonable after consulting the nominated adviser.

That does not automatically make it bad. In fact, management may argue the CEO helped secure an asset the company wanted. But investors should still clock the governance angle. When a chief executive is on both sides of a transaction chain, even if disclosed properly, it deserves a bit of extra scrutiny.

MedPal AI’s pharmacy strategy: reactivating patients, care homes and automation-led growth

The company is applying the same playbook it used after buying Universal Pharmacy assets in October 2025. That strategy includes getting patients to re-nominate MedPal as their chosen NHS pharmacy, winning back care home contracts, improving service levels with robotic dispensing, and tying it all into the MedPal app and MedPal Health OS.

That sounds sensible because pharmacy scale is often about repeat volumes, reliability and logistics. If MedPal can use automation and delivery to improve service, there is a genuine commercial argument for patient retention and reactivation.

The company says its robotic systems deliver approximately 99.9% accuracy and support 24/7 same-day and next-day delivery. That is a useful operational selling point, especially in care home dispensing where reliability matters a lot.

MedPal also says its wider businesses – MedPal.clinic, MedPal Health OS and at-home blood test kits – can support customer introductions and data sharing. The broad pitch is an integrated digital health platform rather than a stand-alone pharmacy. That could become a differentiator, although the RNS does not disclose revenue or profitability figures for those other divisions.

What looks positive in this MedPal AI RNS – and what still needs proving

What looks positive

• Price versus historic activity: £310,000 for access to a site with NHS-verified 2024 dispensing of 1 million items looks inexpensive on paper.
• Clear scale logic: Management has tied the acquisition directly to a stated breakeven threshold of 80,000 items per month.
• Evidence of prior capacity: Runcorn alone reportedly exceeded 100,000 items per month throughout 2024, which suggests the infrastructure has handled scale before.
• Operational momentum: Group dispensing volumes have already reached over 40,000 items per month, with the CEO quoting 42,000 currently.

What still needs proving

• Historic volume is not guaranteed volume: Remedi was in administration, so the big question is how much of that patient book can actually be retained or won back.
• Breakeven is pharmacy-level, not group-level: The RNS is careful here. Group profitability depends on more than the dispensing hubs.
• Limited financial detail: The company does not disclose current pharmacy EBITDA, cash balances, integration costs beyond the acquisition, or the lease economics for the new Runcorn site.
• Related party complexity: The structure may be fair, but it is still more complex than a straightforward third-party purchase.

My view on MedPal AI’s Remedi acquisition for retail investors

I think this is a positive RNS, mainly because it gives MedPal a believable route to scale in pharmacy without paying a huge upfront price. The company is not buying a dream here – it is buying a real dispensing operation with verified historical throughput and plugging it into an existing platform.

That said, investors should keep their feet on the ground. The value in this deal depends on execution, not on the historical 2024 numbers alone. Reactivating patients and care home contracts is the whole game.

If MedPal can push monthly volumes from 42,000 towards 80,000, the pharmacy business could start looking materially stronger. If it struggles to recapture the Remedi book, then the attractive acquisition price will not matter nearly as much as bulls hope.

So the simple takeaway is this: strategically smart, financially interesting, but still very much a prove-it story. The next updates on dispensing volumes will matter more than the acquisition headline itself.